TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06252051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
Study: NCT06575699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Hydromorphone Cassette
Description: Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
Study: NCT04964609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmbracePlus
Description: A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
Study: NCT05455554

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowmet-D
Description: Flowmet-D is a non-invasive device that measures blood flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flowmet-D
Description: Flowmet-D is a non-invasive device that measures blood flow.
Study: NCT05353582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative systematic therapy
Description: 6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS+HIPEC
Description: CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRS+HIPEC
Description: CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: 6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: 12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
Study: NCT05455554

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
Study: NCT05803070

Intervention type: DRUG
Intervention: Topical Cetirizine 1 %
Description: topical cetirizine belongs to anti histamines group

Intervention type: DRUG
Intervention: Topical betamethasone valerate 0.1%
Description: topical betamethasone valerate belongs to corticosteroids group
Study: NCT05670223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit&Strong Exercise Program
Description: The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
Study: NCT05973019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
Study: NCT04999306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: one weekly session during 6 weeks (6 sessions of 30min/1 hour).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: one weekly session during 6 weeks (6 sessions of 1 hour).
Study: NCT04799548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
Study: NCT05659862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally assisted behavioral physical activity intervention
Description: Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website.
Study: NCT06568744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention resuscitation
Description: In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: \>14, or an increase \>4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk \>14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk \> 15 mmHg or \>5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care resuscitation
Description: In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
Study: NCT06187571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+MWM
Description: The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
Study: NCT06141304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor was injected subcutaneously to participants twice per day for five consecutive days ten days post DLI.
Study: NCT04851860

Intervention type: DRUG
Group type: OTHER
Intervention: sublingual immunotherapy
Description: sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
Study: NCT05565235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients will receive intraoperative serratus block with bupivacaine
Description: no additives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serratus block with bupivacaine /magnesium
Description: magnesium added

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serratus block with bupivacaine with nalbuphine
Description: nalbuphine added
Study: NCT05214014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Regulatory Т-cells
Description: Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Systemic Sclerosis according to the clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Systemic Sclerosis according to the clinical protocols
Study: NCT06495437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.
Description: The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
Study: NCT04726475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
Description: 300mg CBD-rich hemp-derived formulation in MCT coconut oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
Description: 300mg CBD-rich hemp-derived formulation in MCT coconut oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: 3ml oral dose of MCT coconut oil.
Study: NCT05410236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D bronchial tree model
Description: A detachable 3D printed bronchial tree model
Study: NCT05183217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Continence promotion program without tailoring
Description: The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Continence promotion program with tailoring
Description: The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention.
Study: NCT05466994

Intervention type: OTHER
Group type: OTHER
Intervention: IPAD
Description: Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world

Intervention type: OTHER
Group type: OTHER
Intervention: Augmented Reality
Description: Participants will play a game through (devices camera and application) let us participants view the real world
Study: NCT06395298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group PIOMI
Description: A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group NIDCAP
Description: A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
Study: NCT06056882

Intervention type: OTHER
Intervention: CLE-guided cryobiopsy
Description: During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
Study: NCT05603195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508 (IV)
Description: Administered sequential, ascending single intravenous (IV) dose
Study: NCT04950049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: receive 2ml dexamethasone (5mg/ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluted dexamethasone 5ml
Description: receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
Study: NCT05888441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obstacle characteristics
Description: In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obstacle characteristics
Description: In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast.
Study: NCT05546346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable magnet tracking system
Description: In this group, wearable magnet tracking system was used.
Study: NCT05477485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: AIMS program - patient
Description: Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention/Usual care
Description: Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
Study: NCT05642260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention programe
Description: Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
Study: NCT05970588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing Promotion Intervention
Description: Participants will be provided with a standing desk converter to set on top of their existing desk for 4 weeks.
Study: NCT04569747

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pertuzumab+TRASTUZUMAB
Description: Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADJUVANT ENDOCRINE THERAPY
Description: Oral, daily per cycle
Study: NCT05496413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARSTIM
Description: In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STARSTIM
Description: In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.